DNA X, Inc. (SONM): Nasdaq/NYSE listing notice — Sonim appoints Executive Chairman, approves 1-for-18 reverse split; Nasdaq extension to Dec 31

DNA X, Inc.

Michael Mulica appointed Executive Chairman effective Oct 16, 2025; receives $300k salary, $250k annual RSU grant, and $500k RSU award tied to asset purchase with Social Mobile.
Stockholders approved reverse stock split at 1-for-18 ratio, effective Oct 27, 2025, to regain compliance with Nasdaq minimum bid price.
Stockholders also approved increase in authorized shares from 100M to 1B; did not approve 1M share increase in equity incentive plan.
Nasdaq granted extension until Dec 31, 2025 to regain compliance with stockholders' equity minimum of $2.5M; company submitted compliance plan.
Reverse Stock Split will not issue fractional shares; cash in lieu will be paid.

item 3.01 item 5.02 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

DNA X, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

October 17, 2025, the Company received written notification from Nasdaq (the “Extension Notice”) granting the Company an extension through December 31, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Under the terms of the extension, on or before December 31, 2025, the Company must evidence compliance with Nasdaq Listing Rule 5550(b)(1) as set forth in the Extension Notice. The Company intends to satisfy these requirements within the current extension period or, if necessary, to request a further extension from Nasdaq, which would be subject to Nasdaq’s discretion. The Company

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

DNA X, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

October 17, 2025, the Company received written notification from Nasdaq (the “Extension Notice”) granting the Company an extension through December 31, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Under the terms of the extension, on or before December 31, 2025, the Company must evidence compliance with Nasdaq Listing Rule 5550(b)(1) as set forth in the Extension Notice. The Company intends to satisfy these requirements within the current extension period or, if necessary, to request a further extension from Nasdaq, which would be subject to Nasdaq’s discretion. The Company

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

DNA X, Inc.: Amendment to increase authorized shares from 100,000,000 to 1,000,000,000 (effective 2025-10-16).

Change: charter amendment
Effective: 2025-10-16

Exact text from the filing

On October 16, 2025, the Company effected the Authorized Share Proposal by filing a certificate of amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, effective as of such date.

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

DNA X, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-018637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.